1154 related articles for article (PubMed ID: 30390221)
1. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis.
Lattanzi S; Brigo F; Trinka E; Zaccara G; Cagnetti C; Del Giovane C; Silvestrini M
Drugs; 2018 Nov; 78(17):1791-1804. PubMed ID: 30390221
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox-Gastaut Syndrome: A Systematic Review and Meta-Analysis.
Lattanzi S; Brigo F; Cagnetti C; Trinka E; Silvestrini M
CNS Drugs; 2018 Oct; 32(10):905-916. PubMed ID: 30132269
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive Cannabidiol in Patients with Dravet Syndrome: A Systematic Review and Meta-Analysis of Efficacy and Safety.
Lattanzi S; Brigo F; Trinka E; Zaccara G; Striano P; Del Giovane C; Silvestrini M
CNS Drugs; 2020 Mar; 34(3):229-241. PubMed ID: 32040850
[TBL] [Abstract][Full Text] [Related]
5. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
6. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
7. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
[TBL] [Abstract][Full Text] [Related]
8. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA; Zhou R; Jacobson C; Weng J; Cheng E; Lay J; Hung P; Lerner JT; Sankar R
Epilepsy Behav; 2015 Jun; 47():138-41. PubMed ID: 25935511
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy.
Franco V; Perucca E
Drugs; 2019 Sep; 79(13):1435-1454. PubMed ID: 31372958
[TBL] [Abstract][Full Text] [Related]
10. Cannabidiol efficacy and clobazam status: A systematic review and meta-analysis.
Lattanzi S; Trinka E; Striano P; Zaccara G; Del Giovane C; Nardone R; Silvestrini M; Brigo F
Epilepsia; 2020 Jun; 61(6):1090-1098. PubMed ID: 32452532
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
Talwar A; Estes E; Aparasu R; Reddy DS
Exp Neurol; 2023 Jan; 359():114238. PubMed ID: 36206805
[TBL] [Abstract][Full Text] [Related]
12. Cannabis for the Treatment of Epilepsy: an Update.
Gaston TE; Szaflarski JP
Curr Neurol Neurosci Rep; 2018 Sep; 18(11):73. PubMed ID: 30194563
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Devinsky O; Marsh E; Friedman D; Thiele E; Laux L; Sullivan J; Miller I; Flamini R; Wilfong A; Filloux F; Wong M; Tilton N; Bruno P; Bluvstein J; Hedlund J; Kamens R; Maclean J; Nangia S; Singhal NS; Wilson CA; Patel A; Cilio MR
Lancet Neurol; 2016 Mar; 15(3):270-8. PubMed ID: 26724101
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
Devinsky O; Thiele EA; Wright S; Checketts D; Morrison G; Dunayevich E; Knappertz V
Acta Neurol Scand; 2020 Dec; 142(6):531-540. PubMed ID: 32592183
[TBL] [Abstract][Full Text] [Related]
15. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.
Bialer M; Perucca E
Epilepsia; 2020 Jun; 61(6):1082-1089. PubMed ID: 32452568
[TBL] [Abstract][Full Text] [Related]
16. Anti-seizure medications for Lennox-Gastaut syndrome.
Brigo F; Jones K; Eltze C; Matricardi S
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD003277. PubMed ID: 33825230
[TBL] [Abstract][Full Text] [Related]
17. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH
Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.
Thiele EA; Marsh ED; French JA; Mazurkiewicz-Beldzinska M; Benbadis SR; Joshi C; Lyons PD; Taylor A; Roberts C; Sommerville K;
Lancet; 2018 Mar; 391(10125):1085-1096. PubMed ID: 29395273
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Lattanzi S; Trinka E; Russo E; Striano P; Citraro R; Silvestrini M; Brigo F
Drugs Today (Barc); 2019 Mar; 55(3):177-196. PubMed ID: 30938373
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
